Q4 2024 Rani Therapeutics Holdings Inc Earnings Call Transcript
Key Points
- Rani Therapeutics Holdings Inc (RANI) has developed the RaniPill technology, which allows for the oral administration of biologics with bioavailability comparable to subcutaneous injections.
- The RaniPill technology has been clinically validated and is being evaluated across several high-value indications, including obesity and immunology.
- Rani Therapeutics Holdings Inc (RANI) has a robust patent portfolio with over 450 granted patents and pending applications.
- Preclinical studies have shown that the RaniPill can deliver high bioavailability for 19 molecules, including antibodies, peptides, and large proteins.
- The company has successfully completed three phase one studies with the RaniPill, showing it to be well tolerated with no serious adverse events reported.
- Rani Therapeutics Holdings Inc (RANI) faces capital constraints, which limit the advancement of some of its programs.
- The company's cash, cash equivalents, and marketable securities decreased significantly from $48.5 million in 2023 to $27.6 million in 2024.
- Rani Therapeutics Holdings Inc (RANI) recorded an impairment loss of $3.7 million related to certain manufacturing property and equipment.
- Net loss for the full year 2024 was $56.6 million, which includes a non-cash impairment loss and stock-based compensation expenses.
- The company is focusing primarily on the RT-114 program due to financial constraints, potentially delaying other promising programs.
Welcome to the Rani fourth-quarter and full-year 2024 financial results and corporate update conference call. (Operator Instructions) As a reminder, this call is being recorded today, March 31, 2025.
I would now like to turn the conference over to Kiki Patel at Gilmartin Group. Please go ahead.
Thank you, operator. Please turn to slide 2. Joining us on the call today from Rani Therapeutics, our Chief Executive Officer, Talat Imran; and Chief Financial Officer, Svai Sanford.
During this conference call, management will make forward-looking statements that are subject to risks, uncertainties, and assumptions, such as but not limited to those discussed in the risk factor section of the company's filings with the Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q, which identify specific risk factors that may cause actual results or events to differ materially from those described in these forward-looking statements.
These
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
